{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T08:22:32Z","timestamp":1791793352520,"version":"4.3.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T00:00:00Z","timestamp":1573948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>For over 50\u2009years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer. Ocular side effects are uncommon and include blurred vision, conjunctivitis, excessive lacrimation and keratitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a 57-year-old male with metastatic colorectal cancer who had received extensive chemotherapy with 5-Fluorouracil-based regimens for over 12\u2009months. Following his seventh cycle of cetuximab\/FOLFIRI, he developed acute onset global headache, nausea and loss of vision in the right eye. After detailed investigations, including ophthalmologic and neurologic consultations, a diagnosis of optic neuritis was made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Chemotherapy was ceased immediately, and intravenous methylprednisolone (1\u2009g) daily for five\u2009days was commenced. His headache resolved and vision started to improve within 24\u2009h. Three weeks after completion of corticosteroids, constriction of the right visual field had fully resolved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Atypical optic neuritis is an inflammatory optic neuropathy that can be caused by ischaemia, mechanical compression, nutritional deficiency, toxins and drugs. Drug-induced optic neuritis, while rare, is associated with cytotoxic medications including methotrexate, cisplatin, carboplatin, vincristine and paclitaxel. There have only been five previous case reports implicating 5-Fluorouracil in the development of optic neuropathy. The likelihood of the adverse drug reaction due to 5-Fluorouracil was assessed using the Naranjo algorithm. A score of +7 indicates probable causality. Clinicians should be alert to this potential ocular toxicity in order to initiate prompt cessation of treatment and early ophthalmology referral to prevent visual loss and damage to ocular structures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219886640","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:31:57Z","timestamp":1574037117000},"page":"511-516","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature"],"prefix":"10.1177","volume":"26","author":[{"given":"Anant J","family":"Raina","sequence":"first","affiliation":[{"name":"Cancer Care Services, Toowoomba Hospital, Toowoomba, Australia"},{"name":"Rural Clinical School, Faculty of Medicine, The University of Queensland, Toowoomba, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-1891","authenticated-orcid":false,"given":"Peter J","family":"Gilbar","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Toowoomba Hospital, Toowoomba, Australia"},{"name":"Rural Clinical School, Faculty of Medicine, The University of Queensland, Toowoomba, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guranjan D","family":"Grewal","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Toowoomba Hospital, Toowoomba, Australia"},{"name":"Rural Clinical School, Faculty of Medicine, The University of Queensland, Toowoomba, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Holcombe","sequence":"additional","affiliation":[{"name":"Rural Clinical School, Faculty of Medicine, The University of Queensland, Toowoomba, Australia"},{"name":"Toowoomba Ophthalmic Consultants, Toowoomba, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,11,17]]},"reference":[{"key":"bibr1-1078155219886640","first-page":"330","volume":"3","author":"Longley DB","year":"2003","journal-title":"Nature Rev"},{"key":"bibr2-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.11.001"},{"key":"bibr3-1078155219886640","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831020-00003"},{"key":"bibr4-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1080\/01658100802391905"},{"key":"bibr5-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12515"},{"key":"bibr6-1078155219886640","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-55-5-731"},{"key":"bibr7-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930100610"},{"key":"bibr8-1078155219886640","first-page":"565","volume":"68","author":"Adams JW","year":"1984","journal-title":"Cancer Treat Rev"},{"key":"bibr9-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020613600826"},{"key":"bibr10-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-13-42"},{"key":"bibr11-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c3fd00"},{"key":"bibr12-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1159\/000322675"},{"key":"bibr13-1078155219886640","doi-asserted-by":"publisher","DOI":"10.3341\/jkos.2014.55.1.143"},{"key":"bibr14-1078155219886640","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2019.26"},{"key":"bibr15-1078155219886640","first-page":"e4582","volume":"11","author":"Noor A","year":"2019","journal-title":"Cureus"},{"key":"bibr16-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr17-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a059919"},{"key":"bibr18-1078155219886640","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh150"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219886640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219886640","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219886640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:07Z","timestamp":1777688527000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219886640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,17]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1177\/1078155219886640"],"URL":"https:\/\/doi.org\/10.1177\/1078155219886640","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,17]]}}}